Sold as Parasal. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Aminosalicylic Acid (sold as Parasal), with 0 new uses approved and 0 published complete response letters.
| Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseCrohn Disease and Ulcerative Colitis · Anabio R&D | Not applicable | Recruiting | Sep 2, 2026 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative ColitisUlcerative Colitis (UC) · Allama Iqbal Medical College | Phase 1 / Phase 2 | Enrolling by invitation | Aug 26, 2026 |
| Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCEtrasimod, Mesalazine · Sir Run Run Shaw Hospital | Phase 4 | Not yet recruiting | Aug 24, 2026 |
| ND-12 Combined With H-6 for Adult Chronic Inflammatory DiarrheaDiarrhea Chronic, UC - Ulcerative Colitis · The Second Hospital of Nanjing Medical University | Early phase 1 | Recruiting | Aug 17, 2026 |
| AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisUlcerative Colitis (UC), Inflammatory Bowel Disease (IBD) · ENBIOSIS BIOTECHNOLOGIES | Not applicable | Not yet recruiting | Jun 2, 2026 |
| Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.Ulcerative Colitis · Qin Yu | Not applicable | Recruiting | Feb 5, 2026 |
| Pentoxifylline in Patients With Ulcerative ColitisInflammatory Bowel Diseases · Ihab Elsayed Hassan | Phase 2 | Recruiting | Jan 16, 2026 |
| Desloratadine in Patients With Ulcerative ColitisUlcerative Colitis (UC), Ulcerative Colitis · Tanta University | Phase 2 | Recruiting | Jan 12, 2026 |
| Jun 30, 1994 | PaserANDA 74346 | Adaptis | 8 | Marketed |
| — | Parasal, Parasal SodiumNDA 6811 | Panray | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA